Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma
Phase 2
Not yet recruiting
- Conditions
- Hodgkin Lymphoma
- Registration Number
- NCT06045195
- Lead Sponsor
- University of Cologne
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Main Inclusion Criteria:<br><br> - age 18-60<br><br> - advanced stage classical Hodgkin Lymphoma<br><br> - no previous treatment for cHL<br><br>Main Exclusion Criteria:<br><br> - Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma<br><br> - Chemotherapy or radiotherapy in medical history<br><br> - Prior or concurrent disease that prevents treatment according to protocol
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method progression free survival
- Secondary Outcome Measures
Name Time Method